The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is: Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?
This study aims to investigate the potential prognostic benefits of evolocumab in patients with MVD after AMI at 2-year follow-up. The primary endpoint is MACE, defined as a composite of cardiac death, myocardial infarction, stroke, angina-driven coronary revascularization, and rehospitalization for heart failure. This is a multicentre, cohort-based TTE study and the target RCT is the FOURIER trial.
Study Type
OBSERVATIONAL
Enrollment
1,862
Evolocumab 140mg every two weeks
Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
MACE
A composite of cardiac death, myocardial infarction, and rehospitalization for heart failure.
Time frame: 2 years
Death
All-cause death
Time frame: 2 years
Myocardial infarction
Myocardial infarction denotes the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia, according to the Fourth Universal Definition of Myocardial Infarction (2018).
Time frame: 2 years
Rehospitalization for heart failure
Readmissions due to symptoms from clinically diagnosed heart failure with or without reduced left ventricular ejection fraction.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.